{"id":"W2213285461","doi":"10.3747/co.22.2700","title":"Does CDKN2A Loss Predict Palbociclib Benefit?","year":2015,"lang":"en","type":"article","venue":"Current Oncology","topic":"Advanced Breast Cancer Therapies","field":"Medicine","cited_by":18,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"U.S. Food and Drug Administration; Incyte; Pfizer","keywords":"Palbociclib; CDKN2A; Medicine; Letrozole; Kinase; Breast cancer; Estrogen receptor; Oncology; Cancer research; Internal medicine; Cyclin-dependent kinase; Regulator; Cancer; Pharmacology; Metastatic breast cancer; Cell cycle; Biology; Tamoxifen; Cell biology","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":true,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"codex-gemma-dda1882f352a","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001904514,0.000185847,0.0004248928,0.00008724277,0.00004165287,0.000007275456,0.0001397777,0.0001265516,0.0002289397],"category_scores_gemma":[0.0001225245,0.0001139704,0.00008539782,0.0001513874,0.0002396349,0.0001006231,0.00008542221,0.0003140747,0.0001773071],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0004693917,"about_ca_system_score_gemma":0.0003834032,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00001185134,"about_ca_topic_score_gemma":0.0000340232,"domain_scores_codex":[0.9986894,0.00004573307,0.0002779135,0.0003330209,0.0002625489,0.0003913869],"domain_scores_gemma":[0.9988502,0.00007457826,0.0001176305,0.0003487918,0.0002360615,0.0003726978],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.001360496,0.0008279796,0.2078585,0.0001214733,0.000115963,0.0001146804,0.001490177,0.00002382707,0.0003327734,0.001272629,0.005420593,0.7810609],"study_design_scores_gemma":[0.005117292,0.0007941881,0.01341415,0.0000891159,0.00008721908,0.0001623354,0.0003865883,0.00009170363,0.0004739738,0.004771012,0.9744493,0.0001631538],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9481123,0.01194881,0.002208133,0.01540276,0.01285668,0.001021752,0.00008169131,0.0005586286,0.007809221],"genre_scores_gemma":[0.9929677,0.0003727627,0.001504694,0.0006723722,0.002605607,0.0001462487,0.00008432585,0.00005211238,0.001594233],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.9690287,"threshold_uncertainty_score":0.4647578,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1058741046390362,"score_gpt":0.4210296053006268,"score_spread":0.3151555006615906,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}